We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

Bristol-Myers Squibb investors hope that a showdown involving new lung cancer studies on Monday will give the stock a long-awaited boost. The shares have languished ahead of the upcoming American Association for Cancer Research’s annual meeting in Chicago, as Wall Street awaits the lung cancer clash between Bristol-Myers and rival Merck & Co. Bristol-Myers could rise as much as 8% if it can show a response rate that is 10% to 15% better than Merck’s product, according to Credit Suisse analyst Vamil Divan. Disappointing results combined with strong Merck data could send Bristol-Myers down as much as 6%, Divan said. BMO Capital Markets analyst Alex Arfaei expects that the Bristol-Myers data will be disappointing. The drug maker is focusing on a narrower group of patients that would require doctors to conduct additional screening that isn’t currently driving their decision-making. Merck’s patient group is broader, plus the drug maker is already in the lead in lung cancer. A successful ...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now

Would you like to comment on this article?
Register (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.

Commenting is subject to our house rules.